UK Supreme Court reinstates CMA costs order in Pfizer/Flynn dispute

The UK’s Competition and Markets Authority has failed to convince the country’s top court that its enforcement will suffer if it is required to pay companies’ costs when they successfully appeal against its decisions.

Unlock unlimited access to all Global Competition Review content